Olpasiran to prevent a first major coronary event in people with high Lp(a)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial randomizes people with elevated Lp(a) and multiple cardiovascular risk factors or evidence of atherosclerosis to receive olpasiran or placebo and follows them for a first major coronary event (CHD death, myocardial infarction, or urgent coronary revascularization). Eligible participants are age 50 or older with Lp(a) ≥200 nmol/L and no prior acute atherothrombotic events or planned arterial revascularization. The study compares event rates between the olpasiran and placebo groups to determine whether lowering Lp(a) translates into fewer first major coronary events. The trial is conducted at U.S. clinical sites including centers in Alabama.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥50 years
* Lp(a)≥ 200 nmol/L during screening
* Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis

Exclusion Criteria:

* Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
* Prior or planned arterial revascularization
* History of major bleeding disorder

Where it's running

• Advanced Cardiovascular LLC
  Alexander City, Alabama, United States Recruiting
• University of Alabama Birmingham Saint Vincents Birmingham
  Birmingham, Alabama, United States Recruiting
• Birmingham Clinical Research
  Birmingham, Alabama, United States Recruiting
• Alliance For Multispecialty Research - Daphne
  Daphne, Alabama, United States Recruiting
• Eastern Shore Research Institute
  Fairhope, Alabama, United States Recruiting
• Heart Center Research LLC
  Huntsville, Alabama, United States Recruiting

+202 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Amgen Call Center
• Email: medinfo@amgen.com
• Phone: 866-572-6436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Improving Care for underserved older Black patients with cardiovascular and other chronic conditions

  This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07748858

• 4D MRI parameters linked to cardiovascular and cancer disease outcomes

  This study tests whether 4D MRI measurements can predict how cardiovascular diseases and cancer will progress in adults undergoing routine cardiac MRI at a single Korean hospital.

  Recruiting Ulsan University Hospital · Ulsan, Ulsan · NCT07678606

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.